-
Biomarkers: Lessons from Innovators
Chaired by Dr Howard Fillit, Chief Science Officer Alzheimer's Drug Discovery Fund and Dr Stacie Weninger President of FBRI, this virtual dialogue will explore the different experiences, and the lessons from that, of companies and funders innovating in the biomarker field. With opening remarks from Randall Bateman, Charlotte Teunissen, Michael Weiner and Henrik Zetterberg followed by a roundtable discussion for all participants in the dialogue.
-
Roundtable CTAD
Hosted by Dr Joanne Pike, Chair of the World Dementia Council and President & CEO of the Alzheimer’s Association. This working lunch will bring together global leaders, researchers, and industry experts to explore innovation in clinical trials and the development of treatments for Alzheimer’s disease and other dementia. The lunch takes place during CTAD 2026 held in San Diego.
Innovation is the engine of progress in dementia research, fueling breakthroughs that move us closer to effective treatments, prevention strategies, and ultimately, cures. The development of disease-modifying therapies marks a new era — one that demands an intensified focus on innovation in brain health and beyond just basic science.
From clinical applications to new approaches in care and technology, innovation is accelerating the discovery of new treatments, enhancing diagnostic capabilities, and refining prevention strategies. The landscape is evolving rapidly, with advances in biomarkers, artificial intelligence, precision medicine and novel therapeutic approaches reshaping what is possible.
To sustain this momentum, we must foster an ecosystem that encourages collaboration, incentivizes risk-taking, and integrates scientific, regulatory and commercial efforts. The World Dementia Council will convene a series of dialogues and meetings to bring together leaders in innovation, discuss the public policy environment, and explore how we can accelerate progress. Our aim is to develop a series of papers that examine not only scientific breakthroughs, but also how innovation can drive equity, improve care, and address the public policy challenges facing the global dementia community.